Business
GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies
GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies\nGBS Global Biopharma's proprietary neuropathic pain therapies are orally-delivered, time-released nanoparticles containing myrcene and other cannabinoid-based ingredients\nPR Newswire\nOTTAWA, Ontario, May 28, 2019\n\n\n\nOTTAWA, Ontario, May 28, 2019 /PRNewswire/ -- GBS Global Biopharma, Inc. (\"GBS Global\"), a Canadian-based subsidiary of GB Sciences, Inc. (OTCQB:GBLX), announced preclinical studies on their proprietary chronic-neuropathic pain formulations in collaboration with the National Research Council (\"NRC\") Canada under the direction of Dr. Lee Ellis at NRC laboratories in Halifax, Nova Scotia. Growing public and government concerns regarding opioid abuse make novel pain treatments a promising field of research and development. Because people are living longer around the world, the global chronic pain treatment market is expected to reach $105.9 billion by 2024.\n\n \n \n\n \n\"Bringing our chronic-neuropathic pain formulations into preclinical animal studies is an important milestone in the development of these patent-pending, time-released formulations,\" said Dr. Andrea Small-Howard, Chief Science Officer and Director of GBS Global. \"We are very fortunate to be working with Dr. Ellis on this important project because of his unique experience in developing novel animal models for studying pain therapies and his track record of publications on the efficacy of cannabinoid-based therapies. Dr. Ellis and his team have also been performing preclinical animal testing on the safety and efficacy of GBS Global's Parkinson's disease therapies, so we know that they are great collaborators.\"\nProviding sustained relief from chronic-neuropathic pain would bring quality of life to tens of millions of patients throughout the world who suffer from conditions...